+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2023
  • Region: Global
  • Grand View Research
  • ID: 4538764
Description Jump to:
The global rare hemophilia factors market size is expected to reach USD 499.5 million by 2030, registering a CAGR of 6.9% from 2023 to 2030. Several factor concentrates gaining marketing approvals from regulatory bodies, such as the U. S. FDA, are expected to provide a significant push to the market growth. In addition, the rising adoption of prophylaxis treatment by patients is expected to boost market growth in the coming years. Patients with severe rare hemophilia factor disorders are recommended prophylactic treatment to avoid bleeding episodes and improve quality of life. The COVID-19 pandemic had a significant impact on the market growth.

The pandemic's emphasis on patient safety and infection control measures led to an increased awareness and importance placed on safety measures in the administration of specific clotting factor therapies. Healthcare providers and patients became more conscientious about following hygienic practices during treatment administration, such as proper disinfection, hand hygiene, and the use of personal protective equipment. This increased emphasis on patient safety measures may have long-term benefits for the administration of rare hemophilia factors. Despite the challenges posed by the pandemic, there was still a high demand for specific clotting factor therapies for rare hemophilia. Patients with rare hemophilia types still required these therapies to effectively manage and treat their condition.

Favorable government initiatives and mandates to increase diagnosis and treatment rates are boosting market growth. For instance, the U. S. Congress enacted the Orphan Drug Act (ODA) in 1983. From 1983 to 2015, around 3,647 drugs were designated the status of orphan drugs, and 554 drugs were approved by the U. S. FDA. The market players are constantly undertaking initiatives, such as innovative product launches and collaborations, to gain an advantage in the highly competitive market. For instance, in November 2022, the FDA announced its approval of an innovative gene therapy for the treatment of genetic blood-clotting Hemophilia B disorder. Kymriah, the gene-based therapy, is used for the treatment of B-cell precursor hemophilia patients below 25 years of age.

Rare Hemophilia Factors Market Report Highlights

  • Based on types, the factor VII segment accounted for the largest revenue share of 32.5% in 2022 and is also expected to grow at the fastest CAGR of 7.6% from 2023 to 2030 owing to the increasing prevalence of this factor deficiency
  • Based on treatments, the fresh frozen plasma segment accounted for the largest revenue share in 2022 owing to its ease of consumption and the increasing consumer preferences
  • In 2022, North America dominated the industry with a share of 39.8% owing to the well-established pharmaceutical and medical industry in the region. On the other hand, Asia Pacific is anticipated to grow at the fastest CAGR of 8.2% over the forecast period
  • This is due to the increasing prevalence of child population in countries, such as China and India


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Treatment
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Treatment outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Rare Hemophilia Factors Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Rare Hemophilia Factors Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Rare Hemophilia Factors: Type Estimates & Trend Analysis
4.1. Rare Hemophilia Factors Market: Key Takeaways
4.2. Rare Hemophilia Factors Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Factor I
4.3.1. Factor I market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Factor II
4.4.1. Factor II market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Factor V
4.5.1. Factor V market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Factor VII
4.6.1. Factor VII market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Factor X
4.7.1. Factor X market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Factor XI
4.8.1. Factor XI market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Factor XIII
4.9.1. Factor XIII market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Rare Hemophilia Factors: Treatment Estimates & Trend Analysis
5.1. Rare Hemophilia Factors Market: Key Takeaways
5.2. Rare Hemophilia Factors Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Factor Concentrates
5.3.1. Factor concentrates market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Fresh Frozen Plasma
5.4.1. Fresh frozen plasma market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Cryoprecipitate
5.5.1. Cryoprecipitate market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Rare Hemophilia Factors Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Rare Hemophilia Factors Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Novo Nordisk
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Biogen
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Bayer Healthcare
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Pfizer, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Shire
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Baxalta (Baxter Healthcare)
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. CSL Behring
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Bio Products Laboratory Ltd.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 3 North America rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 4 North America rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 7 Canada rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 8 Canada rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 9 Europe rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 10 Europe rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 11 Europe rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 12 Germany rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 13 Germany rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 14 UK rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 15 UK rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 16 France rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 17 France rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 18 Italy rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 19 Italy rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 20 Spain rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 21 Spain rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 22 Sweden rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 23 Sweden rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 24 Norway rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 25 Norway rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 26 Denmark rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 27 Denmark rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 28 Asia Pacific rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 30 Asia Pacific rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 31 China rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 32 China rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 33 Japan rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 34 Japan rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 35 India rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 36 India rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 37 Australia rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 38 Australia rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 39 Thailand rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 40 Thailand rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 41 South Korea rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 42 South Korea rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 43 Latin America rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 44 Latin America rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 45 Latin America rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 47 Brazil rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 48 Mexico rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 49 Mexico rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 50 Argentina rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 51 Argentina rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa rare hemophilia factors market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 56 South Africa rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 59 UAE rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 60 UAE rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
Table 61 Kuwait rare hemophilia factors market, by type, 2018 - 2030 (USD Million)
Table 62 Kuwait rare hemophilia factors market, by treatment, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Rare hemophilia factors: Market outlook
Fig. 9 Rare hemophilia factors: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Rare hemophilia factors market driver impact
Fig. 15 Rare hemophilia factors market restraint impact
Fig. 16 Rare hemophilia factors market strategic initiatives analysis
Fig. 17 Rare hemophilia factors market: Type movement analysis
Fig. 18 Rare hemophilia factors market: Type outlook and key takeaways
Fig. 19 Factor I market estimates and forecasts, 2018 - 2030
Fig. 20 Factor II market estimates and forecasts, 2018 - 2030
Fig. 21 Factor V market estimates and forecasts, 2018 - 2030
Fig. 22 Factor VII market estimates and forecasts, 2018 - 2030
Fig. 23 Factor X market estimates and forecasts, 2018 - 2030
Fig. 24 Factor XI market estimates and forecasts, 2018 - 2030
Fig. 25 Factor XIII market estimates and forecasts, 2018 - 2030
Fig. 26 Rare hemophilia factors market: Treatment movement analysis
Fig. 27 Rare hemophilia factors market: Treatment outlook and key takeaways
Fig. 28 Factor concentrates market estimates and forecasts, 2018 - 2030
Fig. 29 Fresh frozen plasma market estimates and forecasts, 2018 - 2030
Fig. 30 Cryoprecipitate market estimates and forecasts, 2018 - 2030
Fig. 31 Others market estimates and forecasts, 2018 - 2030
Fig. 32 Global rare hemophilia factors market: Regional movement analysis
Fig. 33 Global rare hemophilia factors market: Regional outlook and key takeaways
Fig. 34 North America market estimates and forecasts, 2018 - 2030
Fig. 35 U.S. market estimates and forecasts, 2018 - 2030
Fig. 36 Canada market estimates and forecasts, 2018 - 2030
Fig. 37 Europe. market estimates and forecasts, 2018 - 2030
Fig. 38 UK market estimates and forecasts, 2018 - 2030
Fig. 39 Germany market estimates and forecasts, 2018 - 2030
Fig. 40 France market estimates and forecasts, 2018 - 2030
Fig. 41 Italy market estimates and forecasts, 2018 - 2030
Fig. 42 Spain market estimates and forecasts, 2018 - 2030
Fig. 43 Sweden market estimates and forecasts, 2018 - 2030
Fig. 44 Norway market estimates and forecasts, 2018 - 2030
Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 47 Japan market estimates and forecasts, 2018 - 2030
Fig. 48 China market estimates and forecasts, 2018 - 2030
Fig. 49 India market estimates and forecasts, 2018 - 2030
Fig. 50 Australia market estimates and forecasts, 2018 - 2030
Fig. 51 Thailand market estimates and forecasts, 2018 - 2030
Fig. 52 South Korea market estimates and forecasts, 2018 - 2030
Fig. 53 Latin America market estimates and forecasts, 2018 - 2030
Fig. 54 Brazil market estimates and forecasts, 2018 - 2030
Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
Fig. 56 Argentina market estimates and forecasts, 2018 - 2030
Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
Fig. 60 UAE market estimates and forecasts, 2018 - 2030
Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • Novo Nordisk
  • Biogen
  • Bayer Healthcare
  • Pfizer, Inc.
  • Shire
  • Baxalta (Baxter Healthcare)
  • CSL Behring
  • Bio Products Laboratory Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedAugust 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 294.7 Million
Forecasted Market Value ( USD ) by 2030 $ 499.5 Million
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A), By Treatment Type (On-demand), By Therapy (Gene Therapy & Monoclonal Antibodies), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A), By Treatment Type (On-demand), By Therapy (Gene Therapy & Monoclonal Antibodies), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 105 Pages
  • Global
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Rare Hemophilia Factors Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 - Product Image

Rare Hemophilia Factors Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

  • Report
  • 182 Pages
  • Global
From
Rare Hemophilia Factor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Rare Hemophilia Factor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 83 Pages
  • Global
From
Hemophilia Market - Forecasts from 2023 to 2028 - Product Image

Hemophilia Market - Forecasts from 2023 to 2028

  • Report
  • 143 Pages
  • Global
From

About the Blood Clotting Factor Market

The Blood Clotting Factor market is a subset of the biotechnology industry that focuses on the development of products used to treat and prevent bleeding disorders. These products are typically derived from human plasma and are used to replace or supplement the body's natural clotting factors. The market is composed of a variety of products, including recombinant clotting factors, plasma-derived clotting factors, and other clotting factor concentrates. These products are used to treat a range of conditions, including hemophilia, von Willebrand disease, and other rare bleeding disorders. The Blood Clotting Factor market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include CSL Behring, Grifols, Octapharma, Kedrion, and Shire. These companies are engaged in research and development activities to develop new products and improve existing ones. Additionally, they are also involved in marketing and distribution activities to ensure that their products reach the right patients. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.